二尖瓣修复失败后再手术对超长期生存的影响:加拿大单中心30年经验
该研究回顾1991至2024年2383例二尖瓣修复术,最终纳入1222例孤立性退行性二尖瓣反流患者。再手术率6.7%,出院时残余MR≥2+是再手术最强预测因子(HR 7.53),再手术未影响长期生存,但再手术前心血管再入院率显著更高。
要点
- 出院残余MR≥2+是再手术最强预测因子(HR 7.53)。
核心结论
- 在高度专业化的二尖瓣修复项目中,因复发性MR行再手术不常见且不损害长期生存。
- 出院时残余MR是修复失败的主要决定因素,及时再手术可恢复临床稳定并显著降低心血管发病率。
研究设计与样本
- 回顾性单中心队列研究,纳入1991年1月至2024年5月间1222例孤立性退行性二尖瓣反流行二尖瓣修复术的患者。
- 排除非黏液瘤病因、既往二尖瓣手术、非修复手术及合并重大干预的患者。
- 结局来自省级行政数据库,主要终点为因复发性MR再手术,次要终点包括长期生存和心血管再入院。
- 多变量分析采用Cox回归和广义线性模型。
主要发现
- 82例(6.7%)发生再手术,早期失败(<1年)占35.4%,其中62%为技术原因;晚期失败(≥1年)占64.6%,主要因疾病进展(35.9%)或纤维化(32.1%)。
- 免于再手术率1年97.6%、5年94.9%、20年88.2%。
- 出院时残余MR≥2+是再手术最强预测因子(HR 7.53;95%CI 4.76-11.90;P<.0001),也是早期功能障碍最强预测因子(HR 10.90;P<.0001)。
- 再手术与未再手术患者长期生存无差异(HR 1.18;95%CI 0.75-1.86;P=.49)。
- 再手术前心血管再入院年化率为0.17次/患者年,再手术后为0.07次/患者年,差异显著(P<.0001,Poisson回归)。
关键数值与推荐
- 再手术率6.7%(82/1222)。
- 免于再手术率:1年97.6%、5年94.9%、20年88.2%。
- 残余MR≥2+预测再手术的HR为7.53(95%CI 4.76-11.90;P<.0001)。
- 再手术与未再手术长期生存HR为1.18(95%CI 0.75-1.86;P=.49)。
- 心血管再入院年化率再手术前0.17次/患者年,再手术后0.07次/患者年(P<.0001)。
临床怎么用
- 二尖瓣修复术中应尽量确保出院时无残余MR≥2+,以降低再手术风险。
- 对修复后出现复发性MR的患者,及时再手术可恢复临床稳定并减少心血管再入院。
- 再手术本身不增加远期死亡风险,不应因担心生存获益而延迟再手术。
局限性
- 回顾性单中心研究,结果可能受选择偏倚和中心经验影响。
- 仅纳入孤立性退行性MR患者,结论外推需谨慎。
- 再手术组样本量较小(82例),可能影响生存分析的统计效能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the incidence, mechanisms, and timing of recurrent mitral regurgitation (MR) requiring reoperation after degenerative mitral valve repair (MVr) and to assess its impact on long-term survival and cardiovascular readmissions in a large single-center cohort with more than 3 decades of follow-up. METHODS: All MVr procedures performed between January 1991 and May 2024 were reviewed (n = 2383). After we excluded patients with nonmyxomatous etiologies, who had previous mitral surgery, with nonrepair procedures, and with associated major interventions, 1222 patients with isolated degenerative MR comprised the final cohort. Outcomes were obtained from a provincial administrative database. The primary end point was reoperation for recurrent MR; secondary end points included long-term survival and cardiovascular readmissions. Multivariable analyses used Cox-based approaches and generalized linear models. RESULTS: Reoperation occurred in 82 patients (6.7%). Early failures (<1 year) represented 35.4% and were predominantly technical (62% of early failures), whereas late failures (≥1 year) accounted for 64.6% and were mainly driven by disease progression (35.9% of late failures) or fibrosis (32.1%). Freedom from reoperation was 97.6% at 1 year, 94.9% at 5 years, and 88.2% at 20 years. Residual MR ≥2+ at discharge was the strongest predictor of reoperation (hazard ratio [HR], 7.53; 95% CI, 4.76-11.90; P < .0001) and of early dysfunction (HR, 10.90; P < .0001). Long-term survival did not differ between reoperated and nonreoperated patients (HR, 1.18; 95% CI, 0.75-1.86; P = .49). Cardiovascular readmissions were significantly more frequent before reoperation, with an annualized rate of 0.17 events per patient-year compared with 0.07 after reoperation; this reduction was highly significant (P < .0001 by Poisson regression). CONCLUSIONS: In a highly specialized mitral repair program, reoperation for recurrent MR is uncommon and does not negatively affect long-term survival. Residual MR at discharge is the principal determinant of repair failure, and timely reoperation restores clinical stability and substantially reduces cardiovascular morbidity.
引用
- Mendoza RE, Mohammadi S, Kalavrouziotis D, et al. Impact of reoperation on very long-term survival in patients with failed mitral valve repair: A 30-year single-center Canadian experience. J Thorac Cardiovasc Surg. 2026. PMID: 41881389. doi:10.1016/j.jtcvs.2026.03.595
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。